Now FDA ClearedTandem Mobi Tubeless
World’s first and only tubeless AID system with up to 7 days of wear.1*
#1 Rated by Healthcare Professionals2
Tandem Mobi System
Tiny pump, big control! Plus, when Tandem Mobi Tubeless becomes available,† it will be the world’s first and only tubeless AID system with up to 7 days of wear.1* One pump, two ways to wear!
t:slim X2 Insulin Pump
This all-in-one system features a slim, sleek, user-friendly color touchscreen and multiple CGM options.‡ It's powered by Control-IQ+ technology, which predicts and helps prevent highs and lows.
Hear from parents, kids, and teens who have experienced the life‑changing benefits of Tandem automated insulin delivery.
My A1c has been amazing since I switched to Tandem. I used to wake up with lows, and that’s really scary. But Tandem is my safety net.
Izzy
diagnosed 2016
Tristan
diagnosed 1997
Kim
Mother to Anna, diagnosed 2020
Eva
diagnosed 2015
Individual symptoms, situations, circumstances, and results may vary.
Choose from a variety of cannula materials, tubing lengths, and insertion angles to fit your needs.
Technology evolves at a rapid pace. That’s why our insulin pumps are capable of remote software updates.
Our mobile and cloud-based applications are designed to help you better manage your diabetes.
Our Support Team (available 24 hours a day, 365 days a year) is staffed by highly trained representatives.
We offer personal pump training to new customers so they can quickly learn our easy-to-use products.
We’re there for you! We can replace your insulin pump to minimize any disruption to your insulin therapy.§
An insulin pump, like a healthy pancreas, delivers one type of insulin. You can use personalized settings on your insulin pump to deliver insulin continuously (basal) or in larger doses for meals (bolus).
What's next?
Whether you're ready to get a Tandem insulin pump, or looking to check insurance coverage, you’ll find everything you need here.
* Tubeless infusion set is cleared for up to 7 days of wear. Cartridge is cleared for 3 days of use.
† Full commercial launch of the new tubeless cartridge and infusion set for Tandem Mobi in the U.S. is planned for the first half of 2027.
‡ CGM sold separately.
§ See warranty terms and conditions for more details at tandemdiabetes.com/legal/warranty
Reference
Note: Study was conducted using a t:slim X2 insulin pump with Control-IQ technology and Dexcom G6 sensor.
1. As of Nov., 2026. Data on file, Tandem Diabetes Care.
2. Seagrove Partners HCP Perspectives (Devices), September 2026 Insulin Delivery Section N=83.
3. Beck RW, et al. Diabetes Technol Ther. 2023;25(5):329-342.
Important Safety Information
RX ONLY. The Tandem Mobi insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is intended for single patient, home use and requires a prescription. The pump is indicated for use in individuals 2 years of age and greater.
t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater.
Control-IQ+ technology is intended for use with compatible interoperable continuous glucose monitors (iCGM), alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ+ technology is not a substitute for your own active diabetes management.
Control-IQ+ technology is intended for the management of type 1 diabetes mellitus in persons 2 years of age and greater and of type 2 diabetes mellitus in persons 18 years of age and greater. Control-IQ+ technology is intended for use in pregnancy complicated by Type 1 diabetes mellitus, provided the linked CGM system is suitable for use in pregnancy.
WARNING: Control-IQ+ technology should not be used in anyone under the age of 2 years old. Control-IQ+ technology should also not be used in patients who require less than a total daily insulin dose of 5 units per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed in order for Control-IQ+ technology to operate safely.
Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit tandemdiabetes.com/safetyinfo for additional important safety information.